TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39692817

Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39692838

Group type: EXPERIMENTAL
Intervention: Urgency Numeric Rating Scale (NRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient Global Rating of Severity (PGRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient Global Impression of Change (PGIC)
Number of subjects: 0
Study: 39693081

Group type: EXPERIMENTAL
Intervention: Brexpiprazole + Sertraline
Number of subjects: 416

Group type: COMPARATOR
Intervention: Sertraline + Placebo
Number of subjects: 416
Study: 39693096

Group type: EXPERIMENTAL
Intervention: Potassium nitrate (KNO3) (6 mmol 3 times daily)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Potassium nitrate (KNO3)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Potassium chloride (KCl)
Number of subjects: 84
Study: 39693097

Group type: EXPERIMENTAL
Intervention: Self-guided online CBT intervention for 12 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Clinician-guided online CBT for 12 weeks
Number of subjects: 168
Study: 39693139

Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS)-based intervention
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: Standard intervention (health insurance representative visit with feedback)
Number of subjects: 2501

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2501
Study: 39693227

Group type: EXPERIMENTAL
Intervention: Mirikizumab 300 mg for weight >40 kg, 5 mg/kg for weight ≤40 kg every 4 weeks during induction; subcutaneous mirikizumab 200 mg (>40 kg), 100 mg (>20 to ≤40 kg), or 50 mg (≤20 kg) every 4 weeks during maintenance therapy.
Number of subjects: 26
Study: 39693244

Group type: EXPERIMENTAL
Intervention: Lidocaine (positive control)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antagonists blocking TRPA1, TRPM8, NaV1.7, and NaV1.8
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Inhibition of TRPA1, TRPM8, and NaV1.7
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NaV1.8 inhibition
Number of subjects: 36
Study: 39693245

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) for 6 months
Number of subjects: 47
Study: 39693261

Group type: EXPERIMENTAL
Intervention: Earlier physical therapy (started within 1 week)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Later physical therapy (started after 6 weeks)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Earlier physical therapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Later physical therapy
Number of subjects: 203
Study: 39693517

Group type: COMPARATOR
Intervention: ATRA/chemotherapy
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: ATRA/i.v.-ATO
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: oral-AAA (ATRA/oral-ATO/ascorbic acid with ATO maintenance)
Number of subjects: 647

Group type: COMPARATOR
Intervention: ATRA/chemotherapy/non-ATO maintenance
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: ATRA/chemotherapy/ATO maintenance
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: oral-AAA
Number of subjects: 647
Study: 39693611

Group type: EXPERIMENTAL
Intervention: Hemin or protoporphyrin IX supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeting ferrochetalase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-targeting BCL-2 and MCL-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased purine and pyrimidine biosynthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elevated heme and purine biosynthesis gene signatures
Number of subjects: 0
Study: 39693720

Group type: EXPERIMENTAL
Intervention: Lowest quartile concentrations of oestrone
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Lowest quartile concentrations of testosterone
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Lowest quartile concentrations of dehydroepiandrosterone
Number of subjects: 5535
Study: 39693827

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 39694040

Group type: EXPERIMENTAL
Intervention: Cyclic fasting-mimicking diet (FMD) regimen, triweekly, 5-day
Number of subjects: 30
Study: 39694102

Group type: EXPERIMENTAL
Intervention: High neighborhood SES (ADI categorized as highest 15%)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: High individual SES (post-high school education)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Combination of high individual and low neighborhood SES
Number of subjects: 615

Group type: COMPARATOR
Intervention: Low individual SES (high school or less)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Low neighborhood SES (ADI categorized as remaining 85%)
Number of subjects: 615
Study: 39694205

Group type: EXPERIMENTAL
Intervention: Budesonide orodispersible tablets (BOT) 0.5 or 1.0 mg, twice daily
Number of subjects: 186
Study: 39694207

Group type: EXPERIMENTAL
Intervention: Efmarodocokin alfa 30 μg/kg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Efmarodocokin alfa 60 μg/kg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Efmarodocokin alfa 90 μg/kg
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vedolizumab
Number of subjects: 192
Study: 39694415

Group type: EXPERIMENTAL
Intervention: Liquid biopsy (LB) using InVisionFirst®-Lung assay
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Liquid biopsy (LB)
Number of subjects: 319
Study: 39694445

Group type: EXPERIMENTAL
Intervention: Sterile covers
Number of subjects: 70

Group type: COMPARATOR
Intervention: No sterile covers
Number of subjects: 70
Study: 39694573

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 340
Study: 39694678

Group type: EXPERIMENTAL
Intervention: eHealth intervention using an electronic wrist device and a mobile application providing healthcare recommendations, physical activity indications, and hygienic and dietary advice.
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual educational materials from the sleep unit.
Number of subjects: 270
Study: 39694787

Group type: EXPERIMENTAL
Intervention: Habitat Risk Score (HRS) for mpMRI analysis
Number of subjects: 34
Study: 39694978

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy item GP5 (GP5)
Number of subjects: 290
Study: 39695117

Group type: EXPERIMENTAL
Intervention: gecacitinib (100 mg BID)
Number of subjects: 105

Group type: COMPARATOR
Intervention: hydroxyurea (500 mg BID)
Number of subjects: 105
Study: 39695262

Group type: EXPERIMENTAL
Intervention: Infected participants
Number of subjects: 654

Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 654
Study: 39695323

Group type: EXPERIMENTAL
Intervention: Psilocybin (0215 mg/kg body weight)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 39695422

Group type: EXPERIMENTAL
Intervention: Menstrual cups
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Traditional pit latrine
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Water source and latrine type
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Traditional pit or ventilated improved pit latrines
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Stream water
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Non-flush toilets
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Increased rainfall
Number of subjects: 436
Study: 39695424

Group type: EXPERIMENTAL
Intervention: Goal-directed perceptual-motor training program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard intervention protocol
Number of subjects: 38
Study: 39695436

Group type: EXPERIMENTAL
Intervention: Tailored, multi-domain, multi-component falls prevention program (SAFE-TECH)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Monthly phone calls assessing fall status, healthcare utilization, physical activity, and exercise self-efficacy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Exercises focusing on strength, balance, coordination, flexibility, and aerobic endurance; weekly educational sessions on falls risk
Number of subjects: 400

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 400
Study: 39695442

Group type: EXPERIMENTAL
Intervention: Clinician predictions (accuracy = 0.63)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine-learning model predictions (accuracy = 0.67)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined clinician predictions with random forest model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random forest model (baseline assessments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion dysregulation as a predictor
Number of subjects: 0
Study: 39695508

Group type: EXPERIMENTAL
Intervention: Brief binocular vision screening protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of distance and near phoria with positive fusional vergence tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comprehensive binocular vision testing protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Step vergence testing of positive fusional vergence
Number of subjects: 0
Study: 39695566

Group type: EXPERIMENTAL
Intervention: Enhanced Multicomponent Proactive Navigator-Assisted Cessation of Tobacco Use (EMPACT-Us)
Number of subjects: 13496

Group type: COMPARATOR
Intervention: Usual care (control group not explicitly mentioned)
Number of subjects: 13496
Study: 39695586

Group type: EXPERIMENTAL
Intervention: Pharmacist-led interventions including medication reconciliation and medication reviews at admission and discharge
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pharmacist-led interventions
Number of subjects: 105
Study: 39695599

Group type: EXPERIMENTAL
Intervention: Training with handmade phantoms for thoracocentesis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Training with handmade phantoms for pericardiocentesis
Number of subjects: 36

Group type: COMPARATOR
Intervention: PGY-3 emergency medicine residents
Number of subjects: 36
Study: 39695613

Group type: EXPERIMENTAL
Intervention: Project Carer Matters caregiver support programme
Number of subjects: 0
Study: 39695628

Group type: EXPERIMENTAL
Intervention: Postoperative delirium prevention, diagnosis, and intervention protocol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study: 39695629

Group type: EXPERIMENTAL
Intervention: Multicomponent therapeutic exercise program supervised by physiotherapists (MoveUS Program)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 108
Study: 39695643

Group type: EXPERIMENTAL
Intervention: CTM Phase 4 (30-min one-on-one consultation and 8, 60-min group meetings with an activity coach)
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: CTM Phase 4
Number of subjects: 1126
Study: 39695675

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CHT) with radiotherapy (RT) including proton and carbon ion RT (CIRT) and stereotactic body radiation therapy (SBRT) with a minimum dose of 40 Gy, conventional fractionation with concomitant fluoropyrimidine-with/without oxaliplatin-based CHT (CRT) in neoadjuvant setting.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CIRT with a dose of 40-60 Gy relative biological effectiveness (RBE) administered with a daily dose fraction ranging between 3 and 4.8 Gy RBE.
Number of subjects: 88
Study: 39695726

Group type: EXPERIMENTAL
Intervention: Heart Priority Programme (add-on intervention with three core elements: assigning a contact person, systematic communication, and follow-up)
Number of subjects: 260
Study: 39695728

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) monotherapy for 7 days
Number of subjects: 513

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAPQ) for 3 days
Number of subjects: 513

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Artesunate (AS)
Number of subjects: 513
Study: 39695768

Group type: EXPERIMENTAL
Intervention: Olaparib (PARP inhibitor)
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Non-BRCA HRRm tumors
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Non-HRRm tumors
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: BRIP1 mutations
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: RAD51C mutations
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: RAD51D mutations
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: PALB2 mutations
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: CCNE1-amplified tumors
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: PIK3CA-mutated tumors
Number of subjects: 2147
Study: 39695798

Group type: EXPERIMENTAL
Intervention: 7-day antimicrobial therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: 14-day antimicrobial therapy
Number of subjects: 106
Study: 39695824

Group type: EXPERIMENTAL
Intervention: Intraoperative virtual reality (VR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham VR plus usual care (Control)
Number of subjects: 100
Study: 39695859

Group type: EXPERIMENTAL
Intervention: Free distance spectacles provided to students with bilateral spherical equivalent < -0.5 D and better-eye presenting distance visual acuity < 6/12, correctable bilaterally to ≥ 6/7.5.
Number of subjects: 625

Group type: COMPARATOR
Intervention: Driving data before receiving spectacles (control condition).
Number of subjects: 625
Study: 39695887

Group type: COMPARATOR
Intervention: Tofacitinib 5 mg BID (n=185)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID (n=316)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Tofacitinib (≥ 1 dose of tofacitinib 2, 5, or 10 mg BID; n=420)
Number of subjects: 420
Study: 39695914

Group type: EXPERIMENTAL
Intervention: One-test intervention arm (PHQ-9 > 10)
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: Multiple-test intervention arm (three consecutive positive PHQ-9 scores)
Number of subjects: 1786

Group type: COMPARATOR
Intervention: Control group (no mobile-based screening)
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1786
Study: 39696004

Group type: EXPERIMENTAL
Intervention: RSM01 monoclonal antibody
Number of subjects: 0
Study: 39696018

Group type: EXPERIMENTAL
Intervention: Good Psychiatric Management (GPM) for 4 months (10 sessions)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Good Psychiatric Management (GPM)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Change in emotional processing
Number of subjects: 76
Study: 39696036

Group type: EXPERIMENTAL
Intervention: Turkish version of the Headache Disability Questionnaire (HDQ)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Turkish version of the HDQ
Number of subjects: 130
Study: 39696092

Group type: EXPERIMENTAL
Intervention: Long-acting G-CSF
Number of subjects: 61

Group type: COMPARATOR
Intervention: Short-acting G-CSF
Number of subjects: 61
Study: 39696098

Group type: EXPERIMENTAL
Intervention: RGS-ICU platform (cognitive stimulation and relaxation protocols)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard ICU care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RGS-ICU platform
Number of subjects: 80
Study: 39696103

Group type: EXPERIMENTAL
Intervention: Static EUonQoL-Kit
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Dynamic EUonQoL-Kit (IRT/CAT)
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: FACT-G and EQ-5L-5D
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Static EUonQoL-Kit (re-test)
Number of subjects: 4500
Study: 39696111

Group type: EXPERIMENTAL
Intervention: Gratitude journaling intervention
Number of subjects: 26
Study: 39696180

Group type: EXPERIMENTAL
Intervention: Coach-guided personalized depression risk communication tool (PDRC)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1000
Study: 39696211

Group type: EXPERIMENTAL
Intervention: First postshift morning after night shift
Number of subjects: 35

Group type: COMPARATOR
Intervention: Second postshift morning after night shift
Number of subjects: 35
Study: 39696255

Group type: EXPERIMENTAL
Intervention: Daily coffee consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate coffee consumption (2-3 cups/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not-daily coffee consumption
Number of subjects: 0
Study: 39696296

Group type: EXPERIMENTAL
Intervention: Integrated Management Team to Improve Maternal-Child Outcomes (IMPROVE) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive Health, Dignity, and Prevention-focused counseling approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing MDT meetings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leadership involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participatory intervention implementation practices
Number of subjects: 0
Study: 39696305

Group type: EXPERIMENTAL
Intervention: SAIA-MOUD intervention delivered at jail-based MOUD program and three referral clinics over a two-year intensive phase.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SAIA-MOUD intervention
Number of subjects: 100
Study: 39696322

Group type: EXPERIMENTAL
Intervention: Online tool for indicating desire to learn personal genetic risk for specific conditions and carrier status.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with a subset of participants.
Number of subjects: 0
Study: 39696393

Group type: EXPERIMENTAL
Intervention: Patient Education STEREOBES (PES) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient Education as Usual (PEU) program
Number of subjects: 0
Study: 39696430

Group type: EXPERIMENTAL
Intervention: Balanced Eaters group
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Focused on Home Cooking group
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Routine Eaters group
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Restaurant Lovers group
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Varied Eaters group
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Men's dietary habits
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Women's dietary habits
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Men's physical activity
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Women's physical activity
Number of subjects: 2509
Study: 39696469

Group type: EXPERIMENTAL
Intervention: Standard cardiac operation, CPB and subzero-balance ultrafiltration
Number of subjects: 40
Study: 39696526

Group type: EXPERIMENTAL
Intervention: Asciminib 40 mg QD add-on to imatinib 400 mg QD
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Asciminib 60 mg QD add-on to imatinib 400 mg QD
Number of subjects: 84

Group type: COMPARATOR
Intervention: Imatinib 400 mg QD continued therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 84
Study: 39696590

Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) to presupplementary motor area (pSMA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) to dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Selected TMS regimen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 120
Study: 39696604

Group type: EXPERIMENTAL
Intervention: 12-week supervised combined exercise program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) group
Number of subjects: 70
Study: 39696609

Group type: EXPERIMENTAL
Intervention: Oral PrEP
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Facilitated access to oral PrEP
Number of subjects: 77

Group type: COMPARATOR
Intervention: Not using PrEP
Number of subjects: 77
Study: 39696639

Group type: EXPERIMENTAL
Intervention: Decision aids (DAs) and clinician shared decision-making (SDM) training
Number of subjects: 0
Study: 39696646

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) and Positive End-Expiratory Pressure (PEEP) modes during extubation-emergence period
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (patients without complications)
Number of subjects: 199
Study: 39696670

Group type: EXPERIMENTAL
Intervention: Deep sedation with sevoflurane 3-4% delivered by an external mask in the lateral decubitus position
Number of subjects: 23
Study: 39696680

Group type: EXPERIMENTAL
Intervention: Amulirafusp alfa (IMM0306) at doses of 40-2000 μg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amulirafusp alfa (IMM0306) at doses of 800-2000 μg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amulirafusp alfa (IMM0306)
Number of subjects: 48
Study: 39696716

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography Angiography (OCTA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20
Study: 39696755

Group type: EXPERIMENTAL
Intervention: pager alerts to accelerate HELP enrollment
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: family care partner-based delirium prevention interventions
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: combined arm with both HELP and family interventions
Number of subjects: 57

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 57
Study: 39697094

Group type: EXPERIMENTAL
Intervention: 5As framework (Ask, Advise, Assess, Assist, Arrange follow-up)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Praise for quitting efforts
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses adjusting for cancer location, self-reported distress, and self-reported coping ability
Number of subjects: 306
Study: 39697096

Group type: EXPERIMENTAL
Intervention: Ultrasound guided microwave ablation
Number of subjects: 113
Study: 39697147

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 1518
Study: 39697177

Group type: EXPERIMENTAL
Intervention: Temporary proximal blood flow arrest during endovascular thrombectomy; 66 participants in this group.
Number of subjects: 131

Group type: COMPARATOR
Intervention: Nonflow arrest during endovascular thrombectomy; 65 participants in this group.
Number of subjects: 131
Study: 39697201

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of PEG-IFN-
Number of subjects: 54
Study: 39697289

Group type: EXPERIMENTAL
Intervention: Workstation ergonomics modifications group (EMG)
Number of subjects: 96